Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 138
Summary
- Conditions
- Diffuse Large B Cell Lymphoma
- Follicular Lymphoma
- Marginal Zone Lymphoma
- Mucosa Associated Lymphoid Tissue
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentIntervention Model Description: This study is a multicentric open-label phase II trial in 3 cohorts of patientsMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03276468
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Guillaume CARTRON, PhD Lymphoma Study Association Principal Investigator: Charles HERBAUX, MD Lymphoma Study Association
Get Well Soon